Project Grant R43TR005928
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $350K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Aurora, CO 80045, USA
Similar Awards
- Federal Grant Award Summary Xgenomes Corp. received a $399,816 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) beginning September 1, 2025, with completion scheduled for August 31, 2026. The company is developing a novel circulating tumor DNA (ctDNA) analysis platform that directly measures both genetic mutations and DNA methylation changes with accuracy approximately 100 times greater than current next-generation...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- Federal Grant Award Summary Avant Genomics, Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I project grant from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), awarded October 1, 2025, with a completion date of September 30, 2026. The company is developing an automated microfluidic-based system that streamlines bisulfite conversion, a critical and time-consuming step in preparing circulating tumor DNA...
- Federal Grant Award Summary Award: Project Grant | Funding Agency: National Center for Advancing Translational Sciences (NCATS) | Program: NCATS (CFDA 93.350) | Awardee: Simplusdx, Inc. | Amount: $306,299 | Award Date: July 1, 2025 | Performance Period: July 1, 2025 – June 30, 2026 Simplusdx, Inc. will develop and validate a rapid point-of-care testing platform for therapeutic drug monitoring of tacrolimus, a critical immunosuppressive medication used in organ transplantation. The project adapts...
- Federal Grant Award Summary Syntr Health Technologies, Inc. received a $406,500 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) on August 15, 2025, with a completion date of August 14, 2027. The award supports the development and commercialization of the SYNTRFUGE, a fully automated centrifugal lab-on-a-chip platform designed to rapidly dissociate solid tumor tissue into single cells for diagnostic analysis. The technology combines...
- Federal Project Grant Award Summary The National Cancer Institute (National Institutes of Health) awarded $414,585 to the University of Connecticut Health Center on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for noninvasive lung cancer detection. The award, with a completion date of April 30, 2029, supports the creation of an improved diagnostic...
- Federal Project Grant Award Summary Syntr Health Technologies, Inc. received a $1,050,276 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) on September 25, 2025, with a completion date of August 31, 2027. The award supports the advancement and automation of the company's FDA-cleared SYNTRFUGE system and SYNTRFPU360 microfluidic platform for rapid tissue processing and microsizing. The technology automates tissue dissociation and processing...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Massachusetts General Hospital a $2.86 million Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) on September 19, 2025, with completion targeted for August 31, 2029. The award funds development and validation of CAMPEX (CRISPR-Accelerated Molecular Profiling of Extracellular Vesicles), an innovative diagnostic platform designed to advance cancer detection and monitoring through liquid...
- Federal Grant Award Summary Micropure Genomics Inc. received a $291,232 Project Grant award from the National Human Genome Research Institute (NHGRI) under the Human Genome Research program (CFDA 93.172), effective September 17, 2025, with a completion date of August 31, 2026. The award supports the development and validation of an automated microfluidic size selection platform, designated mPREP, that utilizes patented electro-hydrodynamic trapping technology to enable rapid, bead-less, and...